2023-09-01
Kancera appoints new Chief Medical Officer
Kancera AB (publ) announces that Dr. Markus Jerling has been appointed as new Chief Medical Officer, effective from September 1, 2023.
Read More
2023-08-18
Kancera provides operational update in connection with release of financial interim report for second quarter
In connection with the release of the financial interim report for the second quarter of 2023, Kancera AB (publ) provides an operational update and announces that top line results from the ongoing FRACTAL study are expected to be presented...
Read More
2023-08-18
Interim Report Second Quarter April 1 – June 30 2023 Kancera AB (publ.), org.no. 556806-8851
The period in brief – financial summary for the second quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 16.5 million (SEK 14.7 million). Operating income for the second quarter amounted to SEK...
Read More
2023-07-24
Newly published research publication confirms the potential for Kancera’s fractalkine blocker KAND567 in cardiovascular disease
Kancera AB (publ) today comments on the potential for its fractalkine blocking drug candidate KAND567 based on a newly published research publication that summarizes clinical research addressing the pathology driving role of fractalkine axis in cardiovascular disease. KAND567 is...
Read More
2023-06-19
Kancera reports dosing of first patient in the KANDOVA study
Kancera AB (publ) today reports that the first patient in the KANDOVA study, a combined phase Ib/IIa study in ovarian cancer, has been dosed with KAND567.
Read More
2023-05-26
Kancera appoints Peter Selin as new Chief Executive Officer
Kancera AB (publ) today announces that Peter Selin is appointed as new Chief Executive Officer (CEO) as of July 1 2023. At the same time, Thomas Olin is appointed as Executive Vice President and Chief Scientific Officer (CSO).
Read More
2023-05-19
Interim Report First Quarter 2023 January 1 – March 31 2023 Kancera AB (publ.), org.no. 556806-8851
The period in briefJanuary – MarchFinancial summary for the first quarter• Net sales amounted to SEK 0 million (SEK 0).• R&D expenses amounted to SEK 15,2 million (SEK10,6 million).• Operating profit for the first quarter amounted to SEK -17.2...
Read More
2023-04-26
Kancera reports start of patient screening for the KANDOVA-study
Kancera today reports that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the Fractalkine blocker KAND567 in ovarian cancer patients, has been started at the Karolinska University Hospital.
Read More
2023-04-24
Kancera has submitted application to conduct First-In-Human study of KAND145
Kancera today reports that the company has submitted the regulatory application to conduct a First-In-Human study of its Fractalkine blocker KAND145.
Read More
2023-03-21
The Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145
Kancera AB (publ) today reports that the Japan patent office has issued a patent that protects the manufacturing processes for Kancera’s Fractalkine blocking drug candidates KAND567 and KAND145.
Read More